三阴性乳腺癌中COX-2、NF-κB及VEGF表达的临床研究

目的研究环氧酶(COX-2)、核因子-κB(NF-κB)及血管内皮生长因子(VEGF)在三阴性乳腺癌中的表达及临床意义。方法选取2010年1月至2014年12月于该院进行乳腺癌治疗的100例患者为研究对象,其中三阴性乳腺癌50例,非三阴性乳腺癌50例,采用免疫组织化学法检测100例患者乳腺癌组织中COX-2、NF-κB及VEGF的表达,并应用D2-40标记检测淋巴管浸润和淋巴管密度,对相关的临床病理资料进行统计分析。结果 COX-2在三阴性与非三阴性乳腺癌中的表达分别为76%、70%,差异无统计学意义(P0.05),VEGF在三阴性乳腺癌病变和非三阴性乳腺癌病变中阳性表达率分别为60%和36%,差异有统计意义(P0.05)。NF-κB在三阴性乳腺癌病变和非三阴性乳腺癌病变中阳性表达率分别为66%和32%,差异有统计意义(P0.05)。三阴性乳腺癌组织中乳腺癌中NF-κB与VEGF,COX-2与VEGF表达呈正相关。结论放化疗是三阴性乳腺癌术后治疗的主要手段,而抑制NF-κB、VEGF和COX-2的表达有望成为治疗三阴性乳腺癌的新靶点,值得研究探索。

Clinical research on COX-2 ,NF-κB and VEGF expression in triple negative breast cancer

Objective To study the cyclooxygenase (COX-2) ,nuclear factor-κB (NF-κB) and vascular endothelial growth factor (VEGF) expression and clinical significance in triple negative breast cancer .Methods From January 2010 to December 2014 ,breast cancer treatment in our hospital 100 patients for the study ,50 patients with triple negative breast cancer ,50 cases of non-triple neg-ative breast cancer was detected by immunohistochemistry ,100 cases of breast cancer were detected by immunohistochemistry in or-ganizations COX-2 ,NF-κB and VEGF expression of lymphatic vessel invasion and lymph vessel density and D2-40 mark detection , statistical analysis of relevant clinical and pathological information .Results COX-2 in triple negative and non-triple negative breast cancer were 76% ,70% ,the difference was not statistically significant (P>0 .05) ,VEGF triple negative breast cancer and non-triple negative breast lesions in cancerous lesions positive expression rates of 60% and 36% ,respectively ,which had significant difference (P<0 .05) .NF-κB in triple negative breast cancer lesions and non-triple negative breast lesions positive expression rate was 66%and 32% ,respectively ,which had significant difference (P< 0 .05) .Triple negative breast cancer NF-κB and VEGF ,COX-2 and VEGF expression was significantly positively related to breast cancer .Conclusion Radiation and chemotherapy is a major means of triple negative breast cancer postoperative treatment ,while inhibiting the NF-κB ,the expression of VEGF and COX-2 is expected to become the new target for treatment of triple negative breast cancer ,is worth exploring .